Hypogammaglobulinemia
Information
- Disease name
- Hypogammaglobulinemia
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT00115778 | Completed | Phase 2 | Intravenous Immunoglobulin (IVIG) in Lung Transplantation | June 2005 | August 2010 |
| NCT00137748 | Completed | Phase 2/Phase 3 | Cytomegalovirus Hyperimmune Globulin (CMV-Ig) Replacement in Hypogammaglobulinemic Lung Transplant Recipients | January 2001 | January 2006 |
| NCT00138697 | Completed | Phase 2/Phase 3 | Kinetics, Efficacy and Safety of IVIG-L in Hypogammaglobulinemia Patients | May 2001 | December 2004 |
| NCT00161993 | Completed | Phase 2 | Safety, Pharmacokinetic and Efficacy Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solution in Patients With Primary Immunodeficiency (Hypo- or Agammaglobulinemia) | June 13, 2002 | September 24, 2003 |
| NCT00278954 | Completed | Phase 3 | Efficacy, Safety and Pharmacokinetics of Gammaplex in Primary Immunodeficiency Diseases. | January 2006 | November 2007 |
| NCT01002755 | Completed | Phase 2 | Lenalidomide and Ofatumumab in Treating Participants With Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | January 19, 2010 | January 31, 2018 |
| NCT01581593 | Completed | Phase 3 | Efficacy and Safety Study of Kedrion IVIG 10% to Treat Subjects With Primary Immunodeficiency (PID) | November 12, 2012 | August 27, 2014 |
| NCT02043379 | Completed | N/A | Post-bypass Prophylactic IVIG in Infants and Neonates | May 2014 | June 2015 |
| NCT02231879 | Completed | Phase 2/Phase 3 | Plerixafor Versus G-CSF in the Treatment of People With WHIM Syndrome | October 14, 2014 | February 24, 2021 |
| NCT02508584 | Completed | Early Phase 1 | Personalized Immunotherapeutic for Antibiotic-resistant Infection | April 12, 2016 | June 12, 2019 |
| NCT03401268 | Completed | N/A | Subcutaneous Ig in Allogeneic Stem Cell Transplant Recipients | February 1, 2018 | May 1, 2019 |
| NCT04502030 | Recruiting | Phase 3 | Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study) | October 5, 2020 | October 2025 |
| NCT05357781 | Recruiting | Immunoglobulin Deficiency a Treatable Cause of Fatigue in Patients With Multiple Sclerosis (MS)? | July 1, 2022 | December 30, 2026 | |
| NCT05645107 | Recruiting | Phase 3 | A Study to Evaluate Efficacy, Safety, and Pharmacokinetics of XEMBIFY® Plus Standard Medical Treatment (SMT) Compared to Placebo Plus SMT to Prevent Infections in Participants With Hypogammaglobulinemia and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia | December 26, 2022 | June 2026 |
| NCT05678621 | Recruiting | Phase 2/Phase 3 | Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Immunoglobulin Stopping or Extension | November 30, 2022 | April 2027 |
| NCT01981785 | Unknown status | Investigation of Immune Disorders and Deficiencies | December 2012 | December 2018 | |
| NCT04283747 | Unknown status | Rituximab-Induced Hypogammaglobulinemia in Multiple Sclerosis | February 28, 2020 | December 2022 | |
| NCT04447937 | Unknown status | Immunodeficiency in MS | June 29, 2020 | July 30, 2021 |